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Executive summary 
The fast development of vaccines is an essential part of the long-term solution to 
COVID-19, but vaccine development has high costs and carries the risk of high failure rates.
There are currently too few promising projects in the clinical trial pipeline to guarantee 
at least one vaccine soon. More projects need to pass through the development pipeline in 
parallel. Vaccines should ultimately be widely available to all who need them at low cost.
Private life-sciences companies under-invest in vaccine development, especially 
when compulsory licensing and/or price regulations are imposed. Public funding is needed 
to reduce the risks of investing in vaccine development, and also to balance compulsory 
licensing and/or price regulations with incentives for private firms.
The public funding being put into identifying COVID-19 vaccines is too limited to carry 
enough projects through so that at least one vaccine, and preferably more, become available 
at large scale and low cost. Public budgets for these efforts need to be multiplied up several 
times over. We propose a staged support scheme to tackle the COVID-19 vaccine challenge 
and a moon shot programme to meet the challenge of future pandemics. We calculate the 
public budget needed to ensure supply of COVID-19 vaccines. Although substantial, the 
budget represents a bargain compared to the avoided health, social and economic costs.
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1 The COVID-19 vaccine challenge
To stop the COVID-19 pandemic, reopen the economy and prevent the pandemic from 
restarting, the world needs vaccines. Given how difficult and costly it is to engineer natural 
immunity, vaccines are critical for helping to build herd immunity to manage the disease. 
But so far, no vaccines (or therapies1) for COVID-19 have been approved by regulatory 
agencies. The genome of the virus was sequenced very quickly and put in the public domain, 
meaning that researchers were within a matter of weeks able to identify several promising 
vaccine candidates. Start-ups, legacy drug makers and research labs have stepped forward 
with plans to develop vaccines or treatments for COVID-19. National and international public 
authorities have pledged funding for treatments and vaccines. There is much hope that a 
COVID-19 vaccine will be available soon – most optimistically in the next six months, though 
the most frequent prediction is 18 months2. 
But many questions remain. Are there enough projects in the pipeline to ensure a vaccine 
soon?  Once successfully developed, can a vaccine be manufactured quickly on a large scale? 
Will it be available at a fair price? Can open access and fair prices be ensured without dis-
couraging private developers? Who should fund the development and production costs? We 
address these questions by examining success rates from previous vaccine-development pro-
jects and matching this, in terms of numbers of projects and funding, with what is currently 
in the pipeline for COVID-19. To ensure the successful development of COVID-19 vaccines in 
the European Union, we propose an EU publicly-funded support scheme.  
2 The long road to vaccine development 
Drug development (for both treatments and vaccines) typically follows a clear path (Figure 1). 
At each stage, the development of a drug might be stopped for technical, medical or econom-
ic reasons. The different stages are characterised by different probabilities of success, and 
strongly varying costs and durations.
Figure 1 shows that the average success rate for drug development is about 10 percent to 
15 percent. The high risk rates imply that society needs many candidate substances at the 
outset of clinical trials to be sufficiently sure of getting a suitable product in the end.
For vaccines, the success rates are higher than for medical drugs in general3. Success rates 
for vaccines that entered clinical trials can range from 20 percent to 40 percent (Figure 2). In 
particular, vaccines for new diseases, such as COVID-19, are more likely to pass the critical 
and expensive phase 3 because there are not yet benchmarks against which efficacy needs to 
be proved.
1 This contribution focuses on the economics of the development of vaccines, but many parts of the analysis would 
also apply to treatments for COVID-19.  Vaccines and treatments are anyway complementary (see Eichenbaum et 
al, 2020).
2 “Dr. Anthony Fauci, the head of the National Institute of Allergy and Infectious Diseases (NIAID), poured cold 
water on Trump’s estimate, saying it would be more like a year to a year and a half.” See https://edition.cnn.
com/2020/03/31/us/coronavirus-vaccine-timetable-concerns-experts-invs/index.html.
3 Fewer studies look at the success rates by type and phase, leading to less-robust estimates of success rates for vac-
cines at the different clinical trial stages. An extreme example is a study by Pronker et al (2013), quoted by Gouglas 
et al (2018), who reported: “In general, vaccine development from discovery to licensure can cost billions of dollars, 
can take over 10 years to complete, and has an average 94% chance of failure.” The success rates we have used are 
based on a large set of studies, with the lowest and highest extremes eliminated.
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Figure 1: A typical trajectory of drug development4
Source: Bruegel. Note: Reported success rates are averages from six review studies, with the minimum and maximum values eliminated. For a list of the review studies, see the Referenc-
es. See also https://en.wikipedia.org/wiki/COVID-19_drug_development.
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Figure 2: Success rates for clinical trials of development for vaccines4
Source: Bruegel based on review studies (see the References).
In addition, the time span for vaccine development can also be expected to be shorter 
than the average for drug development5. All regulatory authorities for medicines have fast-
track procedures. Vaccines go through such fast tracking because they are typically developed 
in response to emergencies, often with no available benchmarks to prove efficiency against. 
Also, agencies can authorise emergency use, allowing vaccines that are still in the process of 
clinical trials to be made available to some patients. This is however only for restricted excep-
4 The research phase before the pre-clinical and clinical development phase is not considered here. This exploratory 
phase may take many years and involve many dead ends. Also not included are production and commercialisa-
tion. The costs of the production and commercialisation stages vary widely.
5 For instance, it took just ten months for the vaccine for Ebola to go from phase 1 to phase 3 trials (The Economist, 
2020).
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tional cases, such as for medical personnel, and never on a large scale.
Repurposed substances – substances already approved for other diseases –can reuse past 
results and typically go much faster through clinical trials, with lower costs and higher success 
rates6. 
Who develops vaccines? 
Exploratory research and the pre-clinical and early stages of clinical trials can be done by 
researchers in research institutes or small firms. At later stages, however, particularly phase 
3 and commercialisation, large life sciences firms typically take over. They have the financial 
resources for these more expensive stages, experience of managing large clinical trials and 
regulatory approval procedures, and they have the commercialisation capability (manufac-
turing, distribution and marketing)7.
In the last few decades, the vaccine industry has been through a major consolidation, leav-
ing only a handful of large life-sciences firms active on the market. The largest life sciences 
companies for vaccine production (in terms of vaccine revenues) are GSK, Merck, Sanofi and 
Pfizer (Statista, 2020). Johnson & Johnson, through its subsidiary Janssen Pharmaceutica, 
currently has the largest number of vaccine projects in preclinical trials (Statista, 2020). 
How is vaccine development financed?
National and international public research money typically funds the initial exploratory 
research phase, often done by university labs or research organisations. Funders include the 
US National Institutes of Health, and the European Union through its multi-annual research 
programmes8. Philanthropists, such as the Bill & Melinda Gates Foundation, are prominent 
funders. Also big life sciences companies provide some funding for vaccine research.
The vaccine development phases, typically done by private companies, are funded either 
by large life-sciences firms themselves or through company partnerships. Their returns from 
investing in vaccine development depend on the exclusive ownership they can obtain of the 
right to use the ultimately approved substance or technology. As ownership of knowledge and 
claims can be identified clearly in drug development, patents are very effective in protecting 
the intellectual property and ensuring exclusive ownership during the patent lifetime. Patents 
are used heavily in this industry. Typically, platform technologies and mechanisms of action 
(how to treat a certain illness with a certain substance) are patented early on in the process. 
The owners of the patents for successful drugs/vaccines might be the original applicants, 
but developers can also acquire patent rights by buying or licensing from others during the 
development process.
External funding for development is available mostly through public-private partner-
ships. Particularly for the later more-expensive clinical trial stages, public funding if pro-
vided at all, is through co-funding with private developers. In the US, the public part of these 
partnerships is channelled through the Biomedical Advanced Research and Development 
Authority (BARDA, https://www.phe.gov/about/barda/Pages/default.aspx). At the EU level 
this is channelled through the Innovative Medicines Initiative (IMI, www.imi.europa.eu), 
a public-private partnership between the EU and the European Federation of Pharmaceu-
tical Industries and Associations (EFPIA). Debt and equity funding for vaccines and other 
initiatives is also provided via the European Investment Bank’s InnovFin Infectious Diseases 
Finance Facility (IDFF). 
6 Hydroxychloroquine, used to treat malaria, is an example seen by many as a potential treatment for COVID-19. It 
has not been fully trialled as a COVID-19 treatment.
7 As an exception, a clinical trial for treatments for COVID-19, planned to involve 3,200 patients in eight European 
countries with severe COVID-19 infections, was started in March 2020 by the French national health research 
agency Inserm. This example shows that even phase 3 can be done without big pharmaceutical companies, and 
can be done with international coordination.
8 For a list of EU-funded research projects on vaccines, relevant for COVID-19, see https://erc.europa.eu/news-
events/magazine/frontier-research-service-coronavirus-epidemic-response.
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Another recent major funder of vaccine development is the global Coalition for Epidemic 
Preparedness Innovations (CEPI), set up in 2017 with a targeted $1 billion fund. Its financing 
partners include the Gates Foundation and a number of countries. The EU, through IMI, is 
also a partner (https://cepi.net). 
3 Specific challenges for COVID-19 vaccine 
projects
On top of the high overall failure rate of clinical trials of vaccines, COVID-19 poses specific 
challenges (The Economist, 2020). 
First, there is no current close substitute vaccine available from other corona- or other 
viruses, which could be repurposed quickly for COVID-19. The 2003 outbreak of SARS (severe 
acute respiratory syndrome), also caused by a coronavirus, was controlled after four months, 
impeding the development of a vaccine. In hindsight, this was unfortunate, as a SARS vaccine 
could have helped to accelerate the development of a COVID-19 vaccine. 
Another challenge is the scale at which the vaccine, when available, needs to be produced 
and made available throughout the world to provide herd immunity. A vaccine made for the 
world has never been done before. The Gates Foundation is already trying to address these 
large-scale manufacturing challenges by funding new factories for potential coronavirus 
vaccines9. 
Nevertheless, existing technologies to develop and manufacture vaccines can be used 
as a platform for a COVID-19 vaccine. Some COVID-19 vaccine projects are based on 
proven approaches to vaccines, which use modified forms of the virus. The advantage of 
this approach is that it is well tested, with a stock of expertise, including for manufacturing. 
However, as it involves cultivating live cells, manufacturing cannot be quickly scaled up. 
Other projects use newer approaches focusing on genetically engineered synthetic vaccines 
that activate the body’s immune response. The active ingredient in these vaccines can be the 
virus’s DNA or RNA (the genetic instructions for building proteins), or the proteins/spikes 
that let the virus enter into human cells. These vaccines can be quickly developed, as scien-
tists only need the virus’s genetic code, which was made available very quickly for COVID-19. 
Such synthetic vaccines should in principle be faster and cheaper to manufacture at large 
scale. However, they face a higher risk of failure in clinical trials. There are no human DNA or 
RNA medicines on the market yet10.
Because each approach carries specific risks, a variety of approaches will be needed to get 
a successful vaccine for COVID-19 through development. Vaccines developed through differ-
ent approaches might also be better suited to specific population subtypes.
9 This is being done though the money could be wasted if vaccines are not developed. See Brianna Moné, ‘Bill Gates 
is funding new factories for 7 potential coronavirus vaccines, even though it will waste billions of dollars’, Business 
Insider, 3 April 2020, available at https://www.businessinsider.nl/bill-gates-factories-7-different-vaccines-to-fight-
coronavirus-2020-4/.
10 For a more detailed description of the various approaches, see, for example, Cohen (2020), Thanh Le et al (2020) 
and The Economist (2020).
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4 The pipeline of COVID-19 vaccine projects
The World Health Organisation by March 2020 had identified more than 40 promising 
COVID-19 vaccine projects11. CEPI by the end of March had identified 78 active projects 
(Thanh Le et al, 2020). The list grows by the week, helped by the genetic code of the virus 
being made available very early on. See the Appendix for more information on current 
vaccine development projects. 
Almost all of the projects are, at time of writing, still exploratory or at the preclinical stage. 
The only projects to have started clinical trials (as recorded on the ClinicalTrials.gov website) 
are Moderna and Inovio in the US and CanSino Biologics in Hong Kong. Two mainland Chi-
nese projects have also started clinical trials12. All of these started clinical trials in March 2020 
and have thus not yet produced results from tests on actual patients, which is when the major 
drop outs occur (Figures 1 and 2). Europe has several projects at the exploratory research or 
preclinical stages, but no projects in clinical trials at time of writing. 
The projects cover various technological trajectories. Projects using the newer but riskier 
genetic engineering technologies are for the moment in the lead: Moderna and CureVac are 
using mRNA (Messenger RNA) technology and Inovio DNA technology in clinical trials. These 
approaches have a clear advantage in speed of development, but come at a greater risk of not 
getting a vaccine successfully through clinical trials, as DNA and mRNA synthetic engineering 
technologies have never been trialled successfully on humans. 
Among the large life-sciences companies, only Johnson & Johnson, Sanofi and Pfizer are 
actively involved in developing a COVID-19 vaccine, in partnership with small biotech or 
research organisations. GlaxoSmithKline (GSK) and Merck, each with substantial experience 
in vaccine development, are not yet directly involved, although GSK is providing its adjuvant 
‘booster’ technology to other developers, including Pfizer.
Nevertheless, engagement in vaccine development by large life-science companies cannot 
be taken for granted. While research institutes stay mostly confined to the early research 
stages, small biotech firms are the typical lead developers for COVID-19. The few trials at the 
time of writing are being carried out by companies that are small and/or inexperienced in 
phase 3 clinical trials and that lack large-scale vaccine manufacturing capability. In addition, 
as small biotech companies do not have deep pockets, external funding for the more expen-
sive later development stages still needs to be secured.  
Of the COVID-19 clinical trial projects underway, external funding for phase 1 has been 
secured by Moderna (from the US National Institutes of Health and CEPI) and Inovio (from 
CEPI and the Gates Foundation). However, neither has yet secured funding for the most 
expensive later stages, nor secured large-scale manufacturing capacity. For the preclinical 
and exploratory research projects funding has been secured only for the early stages, if at all. 
All would have to seek partnerships with large life-sciences companies, or with public and 
philanthropic funders. The German CureVac project is a notable exception. It had the good 
fortune to secure a substantial amount of European public funding from the European Invest-
ment Fund to cover its total development costs. Johnson & Johnson has also secured enough 
funding for the whole pipeline, with the US Biomedical Advanced Research and Development 
11  See https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_Mar26.
PDF?ua=1. The WHO is not directly funding projects, but is involved as coordinating international exchange of 
information, developing and sharing common blueprints, and international cooperation to accelerate diagnostics, 
therapies and vaccines. 
12  The two Chinese projects are from Shenzhen Geno-Immune Medical Institute, a very recently established insti-
tute, funded by the Shenzhen government. There is no information available on their COVID-19 vaccine projects 
on the WHO site, nor on the Institute’s English website. In addition, Xinhua reported on 14 April 2020, the start 
of two more COVID-19 vaccine clinical trials in China, but neither is reported on ClinicalTrials.gov. One of these 
trials is from Sinovac (see the Appendix), and the other is from the Wuhan Institute of Biological Products, a sub-
sidiary of state owned SinoPharm.
The list of COVID-19 
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Authority providing half of their funding. Box 1 provides an overview of what the EU is cur-
rently funding for COVID-19 vaccines. 
Box 1: EU COVID-19 vaccine funding
Prior to the COVID-19 pandemic, the EU already provided €500 million for vaccine and 
vaccination research through the Horizon 2020 research programme (2014-2020). It has 
also co-funded the development of vaccines through IMI (see section 2) and the European 
Investment Bank. 
To respond to COVID-19, the EU has provided emergency funds to support research and 
development of diagnostics, therapeutics and vaccines. A rapid reaction has been made 
possible by the standing budget line for emergency health research that the Commission 
maintains as part of the Horizon 2020 annual work programmes.
• IMI in March 2020 started a fast-track call for projects on development of coronavirus 
therapeutics and diagnostics. Preventive vaccines were explicitly excluded from this call. 
The EU provided €45 million for this call, with the same amount expected to be provided 
by the private partners in IMI.
• Initially €10 million, subsequently increased to €47.5 million, was provided for research 
projects to respond to the COVID-19 pandemic. Of the 18 research projects short-listed for 
funding in March 2020, two were for a potential vaccine:
 − €3M for Sweden’s Karolinska Institutet. Its project will start animal testing soon, with 
first trials on humans expected to begin in 2021 (https://news.ki.se/vaccine-develop-
ment-against-coronavirus-enters-next-phase).
 − €2.7M for a consortium led by Denmark’s AdaptVac, for the development and clinical 
testing of a novel vaccine. The company said it aims for the vaccine to complete initial 
human clinical testing within 12 months (https://www.adaptvac.com/news).
• The March 2020 round of the European Innovation Council  Accelerator call, with a 
budget of €164 million, includes a fast-track for coronavirus relevant proposals; see 
https://ec.europa.eu/info/news/startups-and-smes-innovative-solutions-welcome-2020-
mar-13_en.
• The European Institute of Technology Health opened in April 2020 a call to EIT partners 
to send proposals for COVID-19 projects with rapid implementation. EIT Health will fund 
each project with up to €600,000. Vaccine and drug development are not supported under 
this call. See https://eit.europa.eu/our-activities/opportunities/apply-now-eit-health-
covid-19-support.
CEPI funding and the EU contribution to CEPI 
In January 2020, CEPI (Coalition for Epidemic Preparedness Innovations) announced the 
start of programmes to develop COVID-19 vaccines. On 6 March, CEPI called for $2 billion in 
additional funding these programmes13. CEPI’s total investment in COVID-19 vaccine R&D, at 
time of writing, is $29.2 million.  The EU has contributed to CEPI via Horizon 2020.
5 Are there enough projects and funding in 
13 See https://cepi.net/news_cepi/2-billion-required-to-develop-a-vaccine-against-the-covid-19-virus-2/.
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the pipeline for a COVID-19 vaccine soon?
Based on failure rates of past vaccine development projects (Figure 2), we can predict how 
many projects14 are needed at the start of the COVID-19 clinical trial pipeline, in order to have 
close to certain chance (say 99 percent) of at least one successful vaccine. 
If there is a probability of between 20 percent (pessimistic scenario) and 40 percent 
(optimistic scenario) that COVID-19 vaccine projects that start clinical trials will reach the 
final stage (Figure 1), between nine projects (optimistic scenario) and 21 projects (pessimistic 
scenario) are needed. With only two COVID-19 vaccine projects having started clinical trials 
in the US so far – five when including the Chinese projects – it is not yet sure there will be at 
least one vaccine at the end, even in an optimistic scenario15.
If the cost of the various clinical stages are similar to the costs for drugs in general16, then 
the costs covering the full development of a vaccine associated with a 99 percent probability 
of success will be from €500 million euro in the optimistic scenario of needing only nine pro-
jects starting clinical trials to around €2 billion in the pessimistic scenario in which 21 projects 
are needed. These amounts would cover only clinical development and regulatory approval, 
and not the early research and preclinical trial phases. Costs of production and supply of the 
vaccine are also excluded. 
However, it is not a winner-takes-all race in a search for one successful vaccine. Different 
vaccines might be needed. Multiple pathways to a vaccine are important, as this will help to 
reduce the risks. Multiple vaccines might also address the large-scale production challenge 
and will prevent monopoly bargaining positions at the end of the pipeline, which would 
impede large-scale availability at low prices. Multiple vaccines would also be better address 
differences in effectiveness in view of differences in immunity or tolerance for different 
groups of the population. 
If enough substances are brought forward to enable success with a probability of 99 per-
cent, statistically there will be on average four successful projects. To be 99 percent sure of 
getting at least three different success cases17, about 20 projects should start clinical trials 
in an optimistic scenario (taking the upper bound of success probabilities), and 40 projects 
should start clinical trials in a pessimistic scenario (taken the lower bound of success proba-
bilities). This would increase the cost range to around €725 million (optimistic) to €3 billion 
(pessimistic).
6 The need for public support
14 This section is focusing on the likelihood of securing vaccines. In terms of how long it will take for vaccines to be 
available, we are aligning on the most frequent prediction of about 18 months. 
15 The number of projects needed increases non-linearly with required success rates. In other words, getting in the 
optimistic scenario to an 80 percent success probability would require only three projects compared to the nine 
projects required for a 99 percent success rate. Five projects would already give a 93 percent success rate. We 
believe that in the case of COVID-19, society cannot afford a probability that is not as close as possible to certainty. 
16 As we don’t have reliable estimates of the costs of vaccine-development projects, we use the numbers from general 
drug development reported in Figure 1: €2.5 million for phase 1; €20 million for phase 2, €65-250 million for phase 
3 and €10 million for approval.
17 CEPI’s ideal scenario is to have funding for three successful projects at the end of the pipeline: https://cepi.net/
news_cepi/2-billion-required-to-develop-a-vaccine-against-the-covid-19-virus-2/.
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The social value of a universally accessible COVID-19 vaccine is huge. The health, human 
and economic cost of COVID-19, which would be avoided if there was a vaccine, is difficult to 
appreciate. Even if only early estimates are considered of a global loss of GDP of 6 percent in 
2020 (IMF, 2020) from COVID-19, the cost would be about $5 trillion.
Compared to what is socially desirable, private companies are likely to underinvest or 
invest too slowly in the development of a COVID-19 vaccine. Private companies and their 
investors, when deciding to engage in COVID-19 projects, will balance the development costs 
and risks against the returns they expect, making comparisons to alternative possible projects. 
Companies can decide to shift developers from other, commercially more promising, work 
to COVID-19 or vice versa. If private life-sciences companies do not believe governments will 
allow them to charge high enough prices for a vaccine, in order to recover the costs and risk 
of development, they will only work with limited resources or not at all on the development 
of a vaccine for COVID-19, preferring to focus on other more profitable development pro-
jects. Fully focusing their expertise and attention on COVID-19 requires a proper balancing 
between government intervention and incentives for private firms. Yet, the private business 
case for vaccine development is not straightforward, explaining why the share of private R&D 
expenditure on vaccines compared to other drugs is small18.
Private developers and private funders will want to be compensated by the expected 
returns on vaccine sales in case of success, but vaccines, compared to other drugs, might 
carry greater commercial risks. Vaccines for highly communicable diseases with serious 
negative health effects, such as COVID-19, need to be made widely available to all in need. 
This makes the potential market for these vaccines huge, and would generate the reputational 
gain from giving the world a COVID-19 vaccine it so desperately needs, but these returns on a 
COVID-19 vaccine might not be sufficiently interesting for private drug companies, compared 
to the high cost and risk, and compared to alternative projects. There are several reasons why 
the private profits to be made from developing a COVID-19 vaccine will be drastically below 
the vaccine’s social value:
• Patients will be much more willing to pay for drugs that help them directly, than for 
vaccines that help them in case of an outbreak, and which have positive immunity effects 
against others. 
• These externalities imply that vaccines for highly communicable diseases such as COV-
ID-19 cannot simply be sold to the highest bidders. These vaccines should be available on 
the basis of social needs, not individual willingness and capacity to pay. Generating herd 
immunity to eradicate the pandemic requires access to vaccines for all social classes in 
rich and poor countries and this would require fairly low prices. For these reasons, COV-
ID-19 vaccines are more likely to be purchased by government agencies and at low prices. 
Commercial developers must worry that they cannot negotiate prices freely with govern-
ments, increasing the commercial risks. 
• Finally, the existence of front-runners in COVID-19 vaccine development represents a 
commercial risk to other developers. It implies a significant uncertainty over the size of 
the market. 
With private returns drastically below the COVID-19 vaccine’s social value, public 
intervention is needed to ensure that a socially-sufficient number of vaccine projects are 
under development at a socially-sufficient speed. Public intervention is also needed to have 
vaccines being manufactured and distributed to all that need them and soon (Blanchard, 
2020). This public intervention can take the form of public funding of development, funding 
or provision of manufacturing facilities, conditions on access to the proprietary technology 
of the successful vaccines through compulsory licensing, and/or controls on the prices of 
18 Established pharma companies only devote about 5 percent of their total R&D expenditures on vaccines. See CCVI 
(1993).
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the vaccines. Some countries have already said they will look into compulsory licences for 
COVID-19 vaccines19. The problem with these interventions is that they need to be balanced 
against the incentives for private developers. For this reason, public de-risking of vaccine 
development and fair access should go hand-in-hand.
An additional concern with public intervention is that individual countries might have an 
incentive to underinvest in public support for a COVID-19 vaccine compared to what is glob-
ally socially optimal. Individual countries might bet on acquiring foreign solutions when they 
become available, instead of spending their own financial, medical and research resources. 
The countries that are able to provide finance should collaborate, with a commitment to 
supply the successful vaccines to all countries in need. 
7 Our proposal
Although the pipeline of COVID-19 vaccine projects at the exploratory and preclinical stages 
is substantial, and there are public funding initiatives, more projects are needed and more 
public money than currently should be put into getting them through clinical trials. 
Based on past clinical trial success rates, we calculated that at least nine projects starting 
clinical trials are needed (to have a 99 percent probability of at least one vaccine, using the 
upper bound of success rates). Ideally, more projects are needed to ensure multiple vaccines. 
The current public funding we have been able to identify is too limited to enable a suf-
ficient number of competing projects, in order to be sufficiently sure that vaccines can be 
available quickly. Missing in particular is a commitment to public funding of projects through 
their later, more-expensive stages of development. With a few exceptions (including  CureVac, 
Johnson & Johnson and Sanofi-GSK), and disregarding for now the Chinese projects, typically 
backed by the Chinese state, none of the preclinical projects have secured funding for the 
later stages of development, should they succeed in their early phases. 
Although Europe has projects in the pipeline, it has no projects yet in clinical trials. Most 
European projects are not assured yet of public funding for the later, more-expensive stages 
of development. As it stands currently, European citizens cannot be sure they will be likely 
to have affordable access to a vaccine soon, particularly if vaccines successfully developed 
in the US or China face export restrictions, even though the EU and its members are willing 
to increase funding for the development of COVID-19 vaccines20. To address the possible 
shortfall, an EU funding scheme should be put in place to increase the number and speed of 
projects to get a COVID-19 vaccine through clinical trials. The scheme would involve a series 
of awards or grants, organised as an open continuous call until the critical number of projects 
is reached. The aim would be to identify at least three suitable vaccines at the end of the 
pipeline, with more than 99 percent probability. Public funding would cover the costs of each 
phase and would be conditional on projects starting the phase. Table 1 sets out the scheme of 
awards.
Table 1: COVID-19 vaccines public funding scheme
Numbers and amounts of awards needed for each stage to ensure that at least three vaccines 
19 Germany, Canada, Australia and Chile have all taken steps or are weighing up moves to issue compulsory licences 
more easily. AbbVie gave up its global intellectual property rights for Kaletra, an HIV drug being assessed as a 
COVID-19 treatment, after Israel issued a compulsory licence that enables the country to use it against corona-
virus without the patent holder’s consent. See Donato Paolo Mancini and Hannah Kuchler, 'AbbVie drops patent 
rights for Kaletra antiviral treatment', Financial Times, 23 March 2020, available at https://www.ft.com/con-
tent/5a7a9658-6d1f-11ea-89df-41bea055720b.
20  European Commission president Ursula von der Leyen said on 15 April she would host an "online pledging confer-
ence" on 4 May 2020. See https://ec.europa.eu/commission/presscorner/detail/en/STATEMENT_20_664.
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complete all clinical phases, under optimistic and pessimistic assumptions
Optimistic scenario (high success probabilites, low cost estimates)
Assumed 
success rate
Size of the 
award
No. awards at 
this stage
Total cost of 
awards
Phase 1 40% €2.5 million 18 €45 million
Phase 2 51% €20 million 13 €260 million
Phase 3 85% €65 million 6 €390 million
Approval phase 100% €10 million 3 €30 million
Pessimistic scenario (low success probabilites, high cost estimates)
Phase 1 20% €2.5 million 40 €100 million
Phase 2 32% €20 million 25 €500 million
Phase 3 63% €250 million 10 €2500 million
Approval phase 90% €10 million 5 €50 million
Source: Bruegel (see Figure 2)
Project proposers at each stage would have to agree when receiving an award that on final 
success, the patented technology will be made freely available for manufacturing. This com-
pulsory licensing would be balanced by the full public funding of the development costs, thus 
not jeopardising the incentives for private applicants to engage in development of a COVID-
19 vaccine. 
The total budget required for the scheme would range from €725 million in an optimistic 
scenario to about €3 billion in a pessimistic scenario. The total is driven up by the projects in 
phase 3, representing 80 percent of the total budget in the pessimistic scenario, or somewhat 
more than half in the optimistic scenario. 
Even though the staging of the scheme would help reduce the risks, the required budgets 
are nevertheless substantial and above what could typically be done within the EU budget. 
One way to raise the amount of money to finance the scheme would be to build on the idea 
of corona or recovery bonds, which could use the EU budget as a financial vehicle to borrow 
funds on the market and leverage them for large-scale investments. The EU would not have 
to be the sole funder. With a pledging event, it could collect a pool of money from public and 
philanthropic donors. But the EU should use its capacity to take the lead in setting up the 
financing, by pledging a substantial share of the total amount required. 
It would be a valuable signal if the EU would already today commit to providing funds, 
even if the detailed rules are only spelled out tomorrow. To save time, the organisation of the 
scheme should be done by an agency with a track record in organising funding schemes for 
vaccine development. IMI comes to mind, particularly if it can collaborate closely with the 
European Investment Fund and particularly with CEPI, in which it is already a partner. 
Why would such a scheme be needed, compared to what the EU is already doing? 
• Compared to the normal pipeline of projects funded by the European Commission, a fo-
cus on development rather than research is needed, and not only on the initial stages, but 
through to the end of the pipeline. This requires bigger than normal public funding.
• The division into different phases would mean the bigger amounts only need to be activat-
ed for those projects that reach the more expensive later phases. Staging would avoid the 
need to commit large funds upfront. 
• Under our proposal, contenders would be sure from the start that there is a scheme availa-
ble for funding all stages in case of success, including the more expensive later stages. 
Some projects might have been able to secure full funding from private sources, but only 
those with a high enough probability of being first. Full funding from private sources 
cannot be assured for all the projects that are needed by society at the start, in order to 
generate multiple successful vaccines.
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• The scheme would be run as an open, continuous call, not with fixed call deadlines, and 
with awards given out in parallel rather than serially. Offering the awards in parallel would 
reduce the overall timeline. The same applicants can also apply simultaneously to the 
various calls with multiple projects at different phases. 
• Our proposal does not back one winner initially, nor does it bet on one winner at the 
end. It is calibrated to ensure multiple successful projects at the end. Supporting multiple 
projects at the start would reduce the high risk of clinical trial failures and ensure at least 
three vaccines. 
• The compulsory licensing condition will mean vaccines become available for produc-
tion and distribution at competitive market rates. This compulsory licensing is a clear 
condition ex ante in return for the full public funding of the development costs. It should 
therefore not reduce the incentives for applicants to engage in a COVID-19 vaccine pro-
ject. It also lessens the commercial uncertainty surrounding the use ex post of compulsory 
licensing for COVID-19 by at least some countries, which might deter private companies 
from engaging in the development of a COVID-19 vaccine. 
For COVID-19, it is critical that vaccines should be available at large scale and low cost. 
Our scheme does not include public support for the manufacturing and distribution of the 
successful vaccines. However, it does contribute to addressing this critical challenge. 
• Ensuring multiple vaccines at the end, combined with compulsory licensing, will lead to a 
competitive supply of vaccines at no/low licensing cost, avoiding supply restrictions and 
marked-up prices from firms with market power. The scheme thus avoids the need for 
public funding ex post to provide subsidies so vaccines can be bought by all who need it. 
It also avoids having to deal with the complexity of designing a socially-optimal subsidy 
scheme, to match willingness to pay with needs, and to deal with problems of segmenting 
markets and parallel imports. It should also remove the incentives for private big pharma-
ceuticals firms to go it alone, in the hope of being the first to win the market in search of 
monopoly rents. 
• In addition, the organising agency can set up a taskforce dedicated to finding the capacity 
and funding for manufacturing at large scale for the successful candidates. It can do this 
from the start of the scheme to save time, even when it is not yet clear which projects will 
be successful21. 
• The agency could also plan the optimal distribution of the vaccines to where they are 
needed most within the EU. 
Although the scheme would be an EU initiative activating EU funds to ensure that EU 
citizens have quick access to COVID-19 vaccines, the initiative should not become a ‘fortress 
Europe’. 
• The agency running the scheme should seek out international collaboration with other 
similar initiatives. Having a significant European instrument might provide leverage in 
ex-ante negotiations of international cross-licensing agreements (with the US or China). 
An agreement to cross-license final vaccine technologies would reduce the number of 
projects needed under each programme, reducing the financial burden. Such negotia-
tions are easier to do ex ante than after one of the partners has already found a vaccine. 
• This agency could also coordinate with the appropriate organisations, such as the World 
Health Organisation, to allocate the vaccines worldwide to where they are needed most. 
• The EU would have with this scheme a tool to provide the compulsory licensing terms for the 
successful vaccines it generates, not only within the EU but also to all those around the world 
who need it. The initiative would thus show the EU as a beacon in dark times when leadership 
21  As the Gates Foundation is doing; see footnote 9.
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is critically needed to organise global coordination and deal with the COVID-19 pandemic. 
In addition to this series of awards to address COVID-19, we call for a moon shot pro-
gramme in order to be better prepared for the next pandemic. This would support research 
into new and faster approaches to vaccine development, universal vaccines and broad 
platforms for vaccine development. This programme can involve a normal grant competition. 
It could be done within the regular EU framework programme, but would be best done with 
international coordination, for example with CEPI or the Gates Foundation, which in summer 
2018 (together with Larry Page) launched a $12 million fund for universal vaccine projects. 
One could easily imagine a budget of double that for an EU moon shot at ‘vaccines for the 
future’.
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Appendix: COVID-19 vaccine projects (up to 
15 April 2020)
Although the pipeline of COVID-19 vaccine projects at the exploratory and preclinical stages 
is substantial, and there are public funding initiatives, more projects are needed and more 
public money than currently should be put into getting them through clinical trials. 
Based on past clinical trial success rates, we calculated that at least nine projects starting 
clinical trials are needed (to have a 99 percent probability of at least one vaccine, using the 
upper bound of success rates). Ideally, more projects are needed to ensure multiple vaccines. 
The current public funding we have been able to identify is too limited to enable a suf-
ficient number of competing projects, in order to be sufficiently sure that vaccines can be 
available quickly. Miss
1 COVID-19 vaccine projects in clinical trials (source: ClinicalTrials.gov 
website)
Moderna, US
The frontrunner in vaccine development for COVID-19 is Moderna, a biotech firm based in 
Cambridge, Massachusetts. Moderna’s approach is an mRNA vaccine, a vaccine technology 
which is expected to have a faster development (its mechanism of action is mRNA-1273). The 
first human trial for a vaccine began on 17 March 2020. It has received funding from the US 
National Institutes of Health/NIAID. For its phase 1, it has research funds from CEPI. Moder-
na, in case of success, does not have the manufacturing capacity to supply the vaccine on its 
own. It will have to find this capacity elsewhere. 
CanSino Biologics, Hong Kong
CanSino Biologics Inc., a company founded in 2009, and quoted on the Hong Kong stock 
exchange, develops and manufactures biological vaccines using its adenovirus-based viral 
vector vaccine platform, which also delivered a vaccine for Ebola. Past experience with ade-
novirus type 5 (Ad5) raises concerns about safety (dangerous side effects) and immunity of 
subpopulations to Ad5. CanSino phase 1 clinical trials for a COVID-19 vaccine on 23 March, 
in Wuhan, China, in alliance with the China’s Academy of Military Medical Sciences.
Inovio Pharmaceuticals, US
Inovio Pharmaceuticals, a small biotech firm founded in 1979, has had grants from the Gates 
Foundation and CEPI to accelerate testing of a COVID-19 vaccine which uses the DNA se-
quence for the spike protein by which the virus attaches to and enters human cells, to deliver 
viral antigens. The firm started phase 1 trials in the first week of April 2020. Inovio was able 
start early on COVID-19 in part because it was already testing a vaccine for MERS, another 
coronavirus.
Shenzhen Geno-Immune Medical Institute, CN,
Shenzhen Geno-Immune Medical Institute, founded by the Shenzhen Government in 2016, 
focuses on advanced lentiviral vector technology to develop various therapeutic solutions for 
cancers and other genetic diseases. Based on this technology, it registered to start in March 
2020, two clinical trials for testing synthetically engineered COVID-19 minigenes based on 
multiple viral genes.
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2 Selected COVID-19 pre-clinical projects
The listed projects are from the WHO’s list of vaccine projects (https://www.who.int/blue-
print/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf), checked against 
company websites. COVID-19 projects are only listed where sufficient information could be 
found on company websites. The list includes the six other projects (beyond Moderna and 
Inovio) supported by CEPI.
CEPI-supported projects: 
CureVac, Germany
CureVac a German biotech firm started in 2000, is developing an mRNA vaccine for COV-
ID-19. It is currently still at pre-clinical stage, but expects to start clinical trials by June 2020. It 
is funded by CEPI with an $8 million grant. The company was also offered an €80 million loan 
guarantee by the European Investment Bank to fund development of a manufacturing facility, 
after an alleged attempt by President Donald Trump to acquire the company or its technol-
ogy. The company’s largest shareholder is the co-founder of software company SAP. Another 
major investor in CureVac is the Gates Foundation. 
Novarax, US
Novavax is creating COVID-19 vaccine candidates using its proprietary recombinant protein 
nanoparticle technology platform to generate antigens derived from the coronavirus spike (S) 
protein. Novarax expects to use its proprietary Matrix-M™ adjuvant with its COVID-19 vaccine 
candidate to enhance immune responses. CEPI will provide initial funding to Novavax to 
enable preparations for phase 1 trials.
Institut Pasteur (France), joint with Themis and the University of Pittsburgh.
CEPI will invest an initial $4.9 million in a partnering agreement with the Institut Pasteur-led 
consortium, which will include Themis, an Austrian biotech firm started in 2009, and the Uni-
versity of Pittsburgh, to develop a vaccine candidate against COVID-19 based on an S-protein 
measles-vector technology. In a first step, CEPI funding will support the preclinical testing, 
initial manufacture of vaccine materials, and preparatory work for phase 1 studies.
University of Hong Kong
Researchers at the University of Hong Kong have created a vaccine candidate using a 
weakened version of the flu virus and have adapted it to express the surface protein of the 
COVID-19 virus. This approach has previously been used to develop pre-clinical vaccine 
candidates against MERS. CEPI is providing initial funding to HKU (US$620,000) to undertake 
pre-clinical testing of their vaccine candidate, and will consider additional funding for further 
clinical testing pending results of these pre-clinical studies.
University of Queensland, Australia
The University of Queensland is developing a ‘molecular clamp’ vaccine platform, a trans-
formative technology that enables targeted and rapid vaccine production against multiple vi-
ral pathogens. This is still in pre-clinical. It received funding from CEPI for up to $10.6 million 
for the development of a COVID-19 vaccine. 
University of Oxford, UK
CEPI is also funding the University of Oxford pre-clinical project, based on their adenovirus 
vaccine vector and for the manufacture of vaccine materials required for pre-clinical and 
phase 1 testing. 
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Selected other projects at pre-clinical stage: 
BioNTech, Germany
BioNTech, a small German immunotherapy company started in 2008, will be co-developing 
with Pfizer a vaccine using the German biotech's mRNA-based drug-development platform. It 
expects to start testing its potential coronavirus vaccine in humans by the end of April 2020. 
Takis/Evvivax, Italy
Takis, an Italian biotech company with experience in oncology vaccine through Phase 1 and 
2 prototypes, is working on a prototype for COVID-19, planning to start testing on animals 
soon. Takis/Evvivax is looking for a big life-sciences partner for funding and production.
AdaptVac, Denmark
AdaptVac is leading a consortium for the development and clinical testing of a novel virus like 
particle (VLP) vaccine. The company announced that its goal is to have the vaccine complete 
initial human clinical testing within 12 months. Being one of the 18 research projects which 
were short-listed for EU funding in March 2020, it acquired €2.7 million euro in funding from 
the European Commission. 
eTheRNA, Belgium
eTheRNA a clinical stage biotech company, founded in 2013 as a spinoff of VUB, announced 
on 24 March 2020 that it had formed a consortium with other biotech companies to start 
developing an mRNA vaccine for COVID-19.
Ziphuis Therapeutics, Belgium
Ziphius is a small pre-clinical gene technology company focusing on mRNA vaccines. It an-
nounced on 20 March 2020, it would start on its mRNA platform the development of a vaccine 
against COVID-19: ZIP-1642, working with the University of Gent.
DIOSynVax, UK
DIOSynVax, a spin-out company set up in 2017 at Cambridge University, has received funding 
from the Bill & Melinda Gates Foundation and the UK innovation agency Innovate UK, to 
develop new vaccines for diseases ranging from influenza to Ebola, and has now refocused 
all of its work on COVID-19. The vaccine is being tested in mice to establish if it generates an 
immune response. DIOSynVax is seeking funding to pursue its work further, and a pharma-
ceutical company with which to partner on clinical trials.
Vaxil Bio, Israel
Vaxil Bio is an Israeli biotech company, based at the Weizmann Institute, focused on immu-
no-oncology. In March 2020, they announced that they had identified a coronavirus (COV-
ID-19) vaccine candidate, based on the proprietary VaxHit bioinformatics platform, and had 
started a pre-clinical programme to test its efficacy as a COVID-19 vaccine candidate.
Heat Biologics, US
Heat Biologics Inc. is a US biotechnology company, founded in 2008, and focused on cancer 
immunotherapy. It announced in mid-March 2020 a strategic collaboration with the Universi-
ty of Miami Miller School of Medicine to support the development of a vaccine leveraging its 
proprietary gp96 platform designed to target the coronavirus that causes COVID-19.
Vaxart, US
Vaxart, a clinical-stage biotechnology company developing oral recombinant vaccines admin-
istered by tablet rather than by injection, announced mid-March 2020 that it has entered into 
an agreement with Emergent BioSolutions, with Emergent deploying its molecule-to-market 
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contract development and manufacturing services to help develop and manufacture Vaxart’s 
experimental oral vaccine candidate for coronavirus disease (COVID-19). Vaxart’s oral recom-
binant vaccine candidate is based on its proprietary VAAST platform.
GeoVax, US and BravoVax, China
GeoVax, a biotechnology company based in Atlanta US, together with BravoVax, a vaccine 
developer in Wuhan, China, announced in January 2020, their intention to jointly develop 
a vaccine against the new coronavirus. GeoVax will use its MVA-VLP vaccine platform and 
expertise to design and construct the vaccine candidate. BravoVax will provide further de-
velopment, including testing and manufacturing support, as well as direct interactions with 
Chinese public health and regulatory authorities.
Greffex, US
Greffex, a US genetic engineering company, said in March 2020 it was ready to move to 
animal testing of a COVID-19 vaccine. Greffex is using an adenovirus-based vector vaccine, 
which are genetically engineered. Part of its research is funded by NIH.
Medicago, Canada
Medicago is a clinical-stage biopharmaceutical company using a novel plant-based manu-
facturing and virus-like particle (VLP) technologies to rapidly develop innovative vaccines. It 
announced in mid-March 2020 the successful production a VLP of the coronavirus, ready for 
pre-clinical testing. Medicago expects to start human trials by July/August 2020. This research 
is being partially funded by the Governments of Canada and Quebec.
Sinovac Biotech, China
Sinovac Biotech is making a COVID-19 vaccine by chemically inactivating whole virus parti-
cles and adding an immune booster called alum. Sinovac used the same strategy in the past 
for a SARS vaccine it developed and tested in a phase I clinical trial. On 14 April 2020, Xinhua 
reported that Sinovac had started its clinical trials. It has however not yet been reported on 
the ClinicalTrials.Gov website (as of 15 April 2020). 
Clover Biopharma, China
Clover, a Chinese (Chengdu) biotech company, founded in 2007, is using its proprietary Tim-
er-Tag© technology that has been shown to be recognised by antibodies produced by multiple 
previously-infected coronavirus patients, to develop its S-Trimer as a vaccine candidate. This 
is still at pre-clinical stage, with no announcement yet of when clinical trials could start.
3 Selected COVID-19 vaccine projects at research institutes (source: 
Bruegel based on WHO and/or research lab’s websites)
Karolinska Institutet, Sweden
At Karolinska Institutet, virus researchers Ali Mirazimi and Matti Sällberg are working to 
develop a prototype vaccine against the new coronavirus. Several vaccine candidates are 
currently available, which target those parts of the virus that are genetically stable and that 
therefore can protect against other types of coronaviruses as well. The first animal studies 
were expected to begin at the end of March, with the first trials in humans expected to begin 
in 2021. It is one of the projects selected by the EU in its March 2020 call, receiving €3 million. 
For later phases, it “will need more money or a collaboration with a pharmaceutical compa-
ny”. See https://news.ki.se/vaccine-development-against-coronavirus-enters-next-phase
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University of Copenhagen, Aarhus University and the Serum Institute, Denmark
Have received DKK25 million (€3.3 million) from the Carlsberg Foundation to develop a vac-
cine against COVID-19 in a short time, based on a promising but previously untested vaccine 
concept.
Imperial College London, UK 
Robin Shattock, head of mucosal infection and immunity within the department of infectious 
disease at Imperial College London, is leading an effort to create an mRNA vaccine against 
coronavirus. 
Oxford University, UK
Researchers led by Sarah Gilbert, head of the Jenner Institute’s influenza vaccine and emerg-
ing pathogens programme, are planning a trial on humans of what is touted to be the UK’s 
frontrunner vaccine. The product uses a virus that is genetically modified so it is unable to 
replicate in human cells.
Migal Galilee Research Institute, Israel
Researchers at this Israeli lab are working to adapt a vaccine initially developed to prevent 
respiratory disease in poultry for the prevention of COVID-19. The government-funded 
institute hailed a scientific breakthrough in February when it isolated COVID-19, with human 
trials for its candidate expected to start by end-April. 
VIDO-InterVac, Canada
The University of Saskatchewan’s Vaccine and Infectious Disease Organisation-International 
Vaccine Centre (VIDO-InterVac) has received C$23 million from the Canadian government 
to expedite work on COVID-19. A test vaccine is being trialled on animals. The lab, which has 
previously worked on vaccines for SARS and the Zika virus, is also exploring alternatives, like 
antiviral medication, that could fill the gap for patients until a vaccine is available.
Fudan University, China
A joint research team from Fudan University, Shanghai JiaoTong University, and RNACure 
Biopharma is currently working on a vaccine for COVID-19.
Tongji University, China
An mRNA vaccine targeting the novel coronavirus is being co-developed by the CDC, Shang-
hai-based Tongji University School of Medicine and Stermirna Therapeutics Co., Ltd. Animal 
tests started in February 2020.
4 Life-sciences firms working on COVID-19 vaccines (source: Bruegel based 
on company websites)
Johnson & Johnson's
Johnson & Johnson's vaccine unit, Janssen Vaccines, based in Flanders, is applying knowl-
edge gained in the development of vaccines for Ebola, Zika and HIV (in partnership with 
Flemish biotech research centres including VIB and REGA) to come up with a new vaccine 
against COVID-19. Like CanSino, its approach uses an adenovirus, Ad26. Phase 1 clinical 
trials are planned to start in September 2020. The budget amounts to $1 billion, with BARDA 
(US) bringing in almost half of the amount. The company claims it can make 600 million vac-
cine doses by the end of 2020 in case of success (of which 300 million will be manufactured in 
the US). It also claims it is engaged in this project on a non-profit basis. 
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Sanofi
Sanofi, through its global vaccines business unit, Sanofi Pasteur, is not active yet in clinical 
trials for a COVID-19 vaccine. It is however leveraging previous development work for a SARS 
vaccine. It is collaborating with BARDA to establish state-of-the-art facilities in the United 
States for the sustainable production of an adjuvant recombinant vaccine that can be used 
for the COVID-19 programme. In addition, Sanofi Pasteur is collaborating with Translate Bio, 
an mRNA therapeutics company, founded in 2011, in Massachusetts (US), to develop a novel 
mRNA vaccine for COVID-19. But this is still very early stage. A spokesperson said Sanofi aims 
to put a vaccine into a phase 1 clinical trial between March 2021 and August 2021.
GSK
GSK, which worked on the swine flu, has plenty of manufacturing knowledge, but is not work-
ing on a vaccine for coronavirus. Instead, it’s offering its drug adjuvant to other developers, 
essentially a booster that can make immunisation more potent. The CEPI-funded University 
of Queensland will have access to the British drugmaker’s vaccine adjuvant platform technol-
ogy. GSK said that Clover Biopharmaceuticals Inc., a Chinese biotechnology company, is also 
using its adjuvant technology in combination with its vaccine candidate, COVID-19 S-Trimer, 
in preclinical studies. GSK and Sanofi said on 14 April that they would join forces: Sanofi with 
its S-protein COVID19 antigen, based on recombinant DNA technology, co-funded by BAR-
DA, and GSK with its adjuvant technology. The companies plan to start phase 1 clinical trials 
in the second half of 2020. They also announced their commitment to making any vaccine 
that is developed through the collaboration affordable to the public and through mechanisms 
that offer fair access for people in all countries.
Pfizer
Pfizer: is jointly working with BioNTEch. See Appendix section 2.
Merck
Merck: A major vaccine company which had a vaccine for Ebola approved in 2019, is not 
working on a coronavirus vaccine. 
